Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Champiat

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2026
Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical TrialsJ-D Fumet, M Roulleaux Dugage, F-X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodiesM Collins, J M Michot, F X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)M Roupret, A Bertaut, G Pignot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 31, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperS Champiat, O Lambotte, E Barreau, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewJ M Michot, C Bigenwald, S Champiat, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2026
Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical TrialsJ-D Fumet, M Roulleaux Dugage, F-X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodiesM Collins, J M Michot, F X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)M Roupret, A Bertaut, G Pignot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 31, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperS Champiat, O Lambotte, E Barreau, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewJ M Michot, C Bigenwald, S Champiat, et al.
Pageof 2